Acutus Medical

 

Best-in-class mapping system for atrial fibrillation ablation procedures

The AcQMap™ is a breakthrough technology which integrates ultrasound and a proprietary mapping platform to provide a map of complex arrythmias with unprecedented accuracy and in real time to guide ablation therapy. The AcQMap™ received CE mark in May 2016.

CEO  Vince Burgess

acutusmedical.com/us

Advent Contact  Shahzad Malik

Advent first invested in the Series A in 2011. Acutus most recently completed a $75m Series C financing in March 2016.
Publicly Listed
6 August 2020 in Acutus Medical, Press Release, Publicly Listed

Acutus Medical Announces Pricing of Initial Public Offering

Press Release.   August 6, 2020 CARLSBAD, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (NASDAQ: AFIB) today announced the pricing of its initial public offering of…
Read More
26 April 2019 in Acutus Medical, Press Release, Publicly Listed

Acutus Medical’s New Contact Mapping Software Receives CE Mark

Press Release.   FDA Clears Robust Second Generation AcQMap Platform CARLSBAD, Calif. and MANNHEIM, Germany, April 26, 2019 – Acutus Medical today announced CE mark approval for AcQMap contact mapping…
Read More
24 October 2017 in Acutus Medical, Press Release, Publicly Listed

Acutus Medical® Receives FDA Clearance for Advanced Cardiac Mapping Technology for Complex Arrhythmias

Press Release.   FDA clearance of the AcQMap® High Resolution Imaging and Mapping System and AcQMap® 3D Imaging and Mapping Catheter is a major milestone for Acutus Medical Clearance allows…
Read More
22 March 2016 in Acutus Medical, Press Release, Publicly Listed

Acutus Medical Completes $75 Million Series C Financing

Press Release.   Expands Existing Blue Chip Syndicate with Institutional and Strategic Investors. Financing Will Support Quest to Transform EP Market by Expanding Clinical Studies and Upcoming European and U.S.…
Read More